

The effect of a low FODMAP diet on luminal microbiota, fermentation and symptoms

Submission date 22/01/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 08/03/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
Last Edited 14/11/2013	Condition category Digestive System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Kevin Whelan

Contact details
4.06 Franklin Wilkins Building
King's College London
150 Stamford St
London
United Kingdom
SE1 9NH

Additional identifiers

Protocol serial number
N/A

Study information

Scientific Title
The effect of a low FODMAP diet on luminal microbiota, fermentation and symptoms: A randomised controlled trial

Study objectives

H0: there will be no significant difference in the concentration of faecal bifidobacteria in patients with Irritable Bowel Syndrome (IBS) following a low FODMAP diet (intervention) compared with those following a normal diet (control) for four weeks.

H1: there will be a significant difference in the concentration of faecal bifidobacteria in patients with IBS following a low Fermentable Oligo-, Di-, and Monosaccharides and Polyol (FODMAP) diet (intervention) compared with those following a normal diet (control) for four weeks.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Guy's Research Ethics Committee, 11/11/2009, ref: 09/H0804/89

Study design

Randomised controlled parallel group trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Irritable bowel syndrome

Interventions

4-week low FODMAP diet compared to usual diet.

Patients in the intervention group will receive individualised dietary advice. A low FODMAP diet is a diet low in poorly absorbed fermentable carbohydrates. Patients will follow the diet for 4 weeks. The total duration of the study will be 5 weeks.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

To assess the effect of a low FODMAP diet on faecal microbiota in patients with IBS. Faecal samples will be collected at baseline and at 4 weeks.

Key secondary outcome(s)

1. To assess the effect of a low FODMAP diet on faecal Short Chain Fatty Acid (SCFA), pH and faecal water in patients with IBS.
2. To assess the effect of a low FODMAP diet on symptoms in patients with IBS.
3. To assess the effect of a low FODMAP diet on stool consistency and frequency in patients with IBS.
4. To assess the nutritional adequacy of a low FODMAP diet in patients with IBS.
5. To assess the acceptability of a low FODMAP diet in IBS patients.
6. Weight and height.

Outcomes will be assessed at baseline and at 4 weeks. Patients will keep a symptom diary and diet diary, and 2 questionnaires will be used to assess nutritional adequacy, FODMAP intake and diet acceptability.

Completion date

31/12/2010

Eligibility

Key inclusion criteria

Patients will be recruited from Gastrointestinal and Dietetic Outpatient clinics at Guys and St Thomas NHS Foundation Trust, London, UK.

1. Adult patients aged 18-65 years
2. Identified as having IBS based on Rome III criteria
3. Symptoms including bloating and/or diarrhoea

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

65 years

Sex

All

Key exclusion criteria

1. Patients with any other gastrointestinal disease or gastrointestinal surgery
2. Patients whose major IBS symptom is constipation
3. Patients receiving lactulose or any other probiotic or prebiotic substances in the four weeks prior to the study
4. Patients who have taken antibiotics in the 4 weeks prior to the study
5. Patients who have received bowel preparation for investigative procedures in the 4 weeks prior to the study
6. Patients with any other significant major organ disorders, including diabetes, psychiatric and current eating disorders
7. Patients who report to be pregnant or lactating
8. Patients who have had changes to IBS medications or dose in the 4 weeks prior to the study

Date of first enrolment

01/02/2010

Date of final enrolment

31/12/2010

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

4.06 Franklin Wilkins Building

London

United Kingdom

SE1 9NH

Sponsor information

Organisation

King's College London (UK)

ROR

<https://ror.org/0220mzb33>

Funder(s)

Funder type

University/education

Funder Name

King's College London (UK)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/08/2012		Yes	No